UBI Ubisoft Entertainment SA

UBISOFT SUCCESSFULLY PRICES A €600 MILLION BOND ISSUE

UBISOFT SUCCESSFULLY PRICES A €600 MILLION BOND ISSUE

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO THE UNITED STATES (EACH AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED) OR IN OR INTO CANADA, JAPAN, AUSTRALIA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS PRESS RELEASE.

UBISOFT SUCCESSFULLY PRICES A €600 MILLION BOND ISSUE

Paris, November 18, 2020 – Ubisoft today successfully priced a €600m, 7-year (due in November 2027) bond issue, with an annual coupon of 0.878%. The order book reached an amount approaching €3bn and was nearly 5 times oversubscribed.

The success of this transaction illustrates investors' strong confidence in Ubisoft’s group strategy and credit profile.

The net proceeds of the bond will be used for general corporate purposes as well as potential future acquisitions. The offering will allow Ubisoft to extend its maturity profile at an attractive cost compared to existing financing instruments and further diversify its debt investor base. This is Ubisoft’s second bond market offering.

BNP Paribas, Crédit Agricole CIB, Commerzbank and J.P. Morgan are acting as Joint Global Coordinators, and HSBC and Société Générale are acting as Joint bookrunners.

Contact

Investor Relations

Jean-Benoît Roquette

SVP Investor Relations

39

Press Relations

Michael Burk

Senior Director of Corporate Public Relations

03

 



 Alexandre Enjalbert

 Senior Investor Relations Manager

  78







 
 

Disclaimer

This press release is for information purposes only and is not an offer to sell or subscribe securities or a solicitation of an order to purchase or subscribe securities in any jurisdiction. The securities mentioned in this press release were not and will not be offered through a public offering other than to qualified investors.

This press release does not constitute an offer for sale of securities in the United States of America or any other jurisdiction in or from which, or to or from any person to or from whom, it is unlawful to make such invitation under applicable securities laws. These securities may not be offered or sold in the United States of America unless they are registered or exempt from the registration requirements of the US Securities Act of 1933, as amended. Ubisoft Entertainment SA does not intend to register any of the securities mentioned in this announcement in the United States or to conduct a public offering of securities in the United States.

This press release is not a prospectus as required under Regulation (EU) 2017/1129 (as amended, the “Prospectus Regulation”). A prospectus will be prepared and made available to the public, in compliance with the Prospectus Regulation, as part of admitting the bonds to trading on the Euronext regulated market in Paris.

This press release does not constitute an offer of securities in France or in any other country. The bonds are the subject of a placement in France and outside France solely to qualified investors as defined in Article 2 point (e) of the Prospectus Regulation and in accordance with Article L. 411-2(1°) of the Monetary and Financial Code.  

Ubisoft Entertainment SA will undertake no action as part of this placement with a view to making a public offering in France or abroad other than to qualified investors. The dissemination of this press release in any country where such dissemination could constitute a violation of applicable legislation is prohibited.

This press release may be sent to persons located in the United Kingdom only under circumstances wherein section 21(1) of the Financial Services and Markets Act 2000 does not apply.

About Ubisoft

Ubisoft is a leading creator, publisher and distributor of interactive entertainment and services, with a rich portfolio of world-renowned brands, including Assassin’s Creed, Far Cry®, For Honor®, Just Dance®, Watch Dogs®, Tom Clancy’s video game series including Ghost Recon®, Rainbow Six® and The Division®. The teams throughout Ubisoft’s worldwide network of studios and business offices are committed to delivering original and memorable gaming experiences across all popular platforms, including consoles, mobile phones, tablets and PCs. For the 2019–20 fiscal year, Ubisoft generated net bookings of €1,534 million. To learn more, please visit: .

© 2020 Ubisoft Entertainment. All Rights Reserved. Ubisoft and the Ubisoft logo are registered trademarks in the US and/or other countries.

Attachment



EN
18/11/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ubisoft Entertainment SA

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
IMAX IMAX CORPORATION
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
EA ELECTRONIC ARTS INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
ZG ZILLOW GROUP INC. CLASS A
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
APP APPLOVIN CORP
ATXS ASTRIA THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
LAC. LITHIUM AMERICAS CORP NEW
ORKA ORUKA THERAPEUTICS INC
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
 PRESS RELEASE

Informations sur les droits de vote et les actions au 31 août 2025

Informations sur les droits de vote et les actions au 31 août 2025    Le 11 septembre 2025 Information relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext ParisCompartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Information mensuelle au 31 août 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Date Nombre total d’actions composa...

 PRESS RELEASE

Informations sur les droits de vote et les actions au 31 juillet 2025

Informations sur les droits de vote et les actions au 31 juillet 2025 Le 6 août 2025 Information relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Place de cotation :        Euronext ParisCompartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                 Information mensuelle au 31 juillet 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Date Nombre total d’actions composant l...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch